A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia
Main Authors: | , , , , , , , |
---|---|
Format: | Conference item |
Language: | English |
Published: |
American Society of Hematology
2021
|